The Budget Impact of Biosimilar Infliximab (Remsima®) for the Treatment of Autoimmune Diseases in Five European Countries

被引：0
|
作者：
Ashok Jha
Alex Upton
William C. N. Dunlop
Ron Akehurst
机构：
[1] Mundipharma International Ltd.,School of Health and Related Research (ScHARR)
[2] Abacus International,undefined
[3] University of Sheffield,undefined
[4] BresMed Health Solutions Limited,undefined
[5] Northchurch Business Centre,undefined
来源：
Advances in Therapy | 2015年 / 32卷
关键词：
Ankylosing spondylitis; Biosimilar; Crohn’s disease; Infliximab; Psoriasis; Psoriatic arthritis; Remicade; Remsima; Rheumatoid arthritis; Ulcerative colitis;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：742 / 756
页数：14
相关论文
共 30 条
  • [1] The Budget Impact of Biosimilar Infliximab (RemsimaA®) for the Treatment of Autoimmune Diseases in Five European Countries
    Jha, Ashok
    Upton, Alex
    Dunlop, William C. N.
    Akehurst, Ron
    ADVANCES IN THERAPY, 2015, 32 (08) : 742 - 756
  • [2] Progress in biosimilar monoclonal antibody development: the infliximab biosimilar CT-P13 in the treatment of rheumatic diseases
    Braun, Juergen
    Kudrin, Alex
    IMMUNOTHERAPY, 2015, 7 (02) : 73 - 87
  • [3] Infliximab Biosimilar (Remsima™) in Therapy of Inflammatory Bowel Diseases Patients: Experience from One Tertiary Inflammatory Bowel Diseases Centre
    Kolar, M.
    Duricova, D.
    Bortlik, M.
    Hruba, V.
    Machkova, N.
    Mitrova, K.
    Malickova, K.
    Lukas, M., Jr.
    Lukas, Milan
    DIGESTIVE DISEASES, 2017, 35 (1-2) : 91 - 100
  • [4] An updated review of infliximab biosimilar, CT-P13, in the treatment of immune-mediated inflammatory diseases
    Hong, Seung Wook
    Kim, Yong-Gil
    Ye, Byong Duk
    IMMUNOTHERAPY, 2020, 12 (09) : 609 - 623
  • [5] Budget impact analysis of infliximab biosimilar: the Italian scenery
    Lucioni, Carlo
    Mazzi, Silvio
    Caporali, Roberto
    GLOBAL & REGIONAL HEALTH TECHNOLOGY ASSESSMENT, 2015, 2 (02) : 78 - 88
  • [6] Budget impact analysis of biosimilar infliximab (CT-P13) for the treatment of rheumatoid arthritis in six Central and Eastern European countries
    Brodszky, Valentin
    Baji, Petra
    Balogh, Orsolya
    Pentek, Marta
    EUROPEAN JOURNAL OF HEALTH ECONOMICS, 2014, 15 : S65 - S71
  • [7] Frequency and characteristics of infusion reactions during biosimilar infliximab treatment in inflammatory bowel diseases: results from Central European nationwide cohort
    Balint, Anita
    Rutka, Mariann
    Vegh, Zsuzsanna
    Kurti, Zsuzsanna
    Gecse, Krisztina B.
    Banai, Janos
    Bene, Laszlo
    Gasztonyi, Beata
    Kristof, Tunde
    Lakatos, Laszlo
    Miheller, Pal
    Palatka, Karoly
    Patai, Arpad
    Salamon, Agnes
    Szamosi, Tamas
    Szepes, Zoltan
    Toth, Gabor Tamas
    Vincze, Aron
    Bor, Renata
    Milassin, Agnes
    Fabian, Anna
    Nagy, Ferenc
    Kolar, Martin
    Bortlik, Martin
    Duricova, Dana
    Hruba, Veronika
    Lukas, Martin
    Mitrova, Katarina
    Malickova, Karin
    Lukas, Milan
    Lakatos, Peter L.
    Molnar, Tamas
    Farkas, Klaudia
    EXPERT OPINION ON DRUG SAFETY, 2017, 16 (08) : 885 - 890
  • [8] Infliximab Biosimilar (CT-P13; Infliximab-dyyb): A Review in Autoimmune Inflammatory Diseases
    Blair, Hannah A.
    Deeks, Emma D.
    BIODRUGS, 2016, 30 (05) : 469 - 480
  • [9] The Rituximab Biosimilar CT-P10 in Rheumatology and Cancer: A Budget Impact Analysis in 28 European Countries
    Gulacsi, Laszlo
    Brodszky, Valentin
    Baji, Petra
    Rencz, Fanni
    Pentek, Marta
    ADVANCES IN THERAPY, 2017, 34 (05) : 1128 - 1144
  • [10] Adoption of Biosimilar Infliximab for Rheumatoid Arthritis, Ankylosing Spondylitis, and Inflammatory Bowel Diseases in the EU5: A Budget Impact Analysis Using a Delphi Panel
    Kanters, Tim A.
    Stevanovic, Jelena
    Huys, Isabelle
    Vulto, Arnold G.
    Simoens, Steven
    FRONTIERS IN PHARMACOLOGY, 2017, 8
123